| Objective: To observe the differences of the rate of glucose metabolism before and after using the silybin in the metabolic syndrome patients.Method: Twenty newly diagnosed patients who met a modified Chinese Medical Association Diabetes Branch (CDS) definition for the metabolic syndrome (MS) in 2004 were matched for age and sex, and both subjects in every pair received either silybin (140mg/d;n=10) or rosiglitazone (4mg/d;n=10) for 12 weeks. The silybin group and rosiglitazone group who were studied with the euglycemic insulin clamp at 0 week were restudied with the euglycemic insulin clamp at twelfth week. As well as we would determin a series of indexes, such as body height,weights waist circumferences blood pressure,fasting blood glucose (FBG),fasting insulin(FINS),fasting C-peptide,cortisol(COR),triglyceride(TCH),total cholesterol(TG),high-density lipoprotein cholesterol(HDL-C) and low density lipoprotein cholesterol(LDL-C). And further we would calculate the body mass index(BMI),body surface area(BSA) and the rate of glucose metabolism.Result: After 12 weeks , the rate of glucose metabolism (i.e.M)of both the silybin group and rosiglitazone group (6.16±1.58 vs 6.58±1.15)were significant higher than pretherapeutic M (P<0.05). Between the two groups , there was not diffence in the statistics(P>0. 05). Meanwhile silybin group could degrade the FBG,FINS and TG at the same time (P<0. 05), but the other indexes didn't have different than pretherapy. SBP,FBG and FINS in rosiglitazone group had conspicuous lower, HDL-C had higher than pretherapy (P<0. 05), but the other indexes also didn' t have different(P>0. 05).Conclusion: The treatment of MS with silybin showed silybin could elevate the rate of glucose metabolism and improve insulin resistance in the metabolic syndrome patients. The effect of silybin approximated to the effect of rosiglitazone. Silybin can degrade the FBG,FINS and TG and there isn't adverse reaction been found. We can think it is safe and efficacious.
|
PDF Full Text Request